Hereditary Cancer
18
3
4
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 18 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 10 completed trials
Clinical Trials (18)
Expanding Genetic Access for Prostate Cancer Survivors
The DIALOGUE Study: Swiss-Korean Billateral Collaboration
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Evaluation of Hereditary Cancer Educational Videos
Addressing Genomic Disparities in Cancer Survivors
CHARGE Study: CHoice ARchitecture Genetic tEsting
Previvors Recharge: A Resilience Program for Cancer Previvors
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
Penn Biobank Return of Research Results Program
Quebec Pancreas Cancer Study
Educational Video Versus In-person Genetic Counseling for Hereditary Cancer
Germline Mutations in Pancreatic Adenocarcinoma
Genetic Risk: Whether, When, and How to Tell Adolescents
Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies
Combined Breast Cancer Risk Study
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes